ANDA 211523

AIZANT

FDA Drug Application

Application #211523

Documents

• Letter: 2019-10-04

Application Sponsors

ANDA 211523

AIZANT

Marketing Status

• None (Tentative Approval): 001
• None (Tentative Approval): 002

Application Products

001	TABLET; ORAL	5MG	0	DAPAGLIFLOZIN	DAPAGLIFLOZIN
002	TABLET; ORAL	10MG	0	DAPAGLIFLOZIN	DAPAGLIFLOZIN

FDA Submissions

UNKNOWN;

ORIG

1

TA

2019-09-27

STANDARD

Submissions Property Types

ORIG

1

Null

31

CDER Filings

AIZANT

cder:Array
(
    [0] => Array
        (
            [ApplNo] => 211523
            [companyName] => AIZANT
            [docInserts] => ["",""]
            [products] => [{"drugName":"DAPAGLIFLOZIN","activeIngredients":"DAPAGLIFLOZIN","strength":"UNKNOWN","dosageForm":"UNKNOWN","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"}]
            [labels] => 
            [originalApprovals] => [{"actionDate":"09\/27\/2019","submission":"ORIG-1","actionType":"Tentative Approval","submissionClassification":"","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2019\\\/211523Orig1s000_TAltr.pdf\"}]","notes":"> Label is not available on this site."}]
            [supplements] => 
            [actionDate] => 2019-09-27
        )

)